MEDVi
US$ 29.30
anesthesia glp-1 guidance news 2025 ADS/ANZCA/GESA/NACOS clinical practice recommendations on the peri-procedural use of GLP-1/GIP receptor agonists Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists:
Description
So it comes down to were they even taking that drug properly
This doesnt mean its a free-for-all
There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see Clinical Considerations)
The following features would enhance the value of an obesity therapeutic, but would likely be assessed in follow-up trials or even post-approval: Additional efficacy in obesity-related co-morbidities
Pharmacokinetic and dose-finding studies on efpeglenatide in patients with type 2 diabetes
Key Factors to Compare 1
